Cargando…

Ipragliflozin lowers small, dense low-density lipoprotein cholesterol levels in Japanese patients with type 2 diabetes mellitus

AIMS: This preliminary randomized, parallel-group comparative study evaluated the efficacy of ipragliflozin for reduction of small dense low-density lipoprotein cholesterol (sd LDL-C) levels in Japanese patients with type 2 diabetes mellitus (T2DM). METHODS: Sixty-two patients with T2DM (age, 56 ± 8...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bando, Yukihiro, Tohyama, Hitomi, Aoki, Keiko, Kanehara, Hideo, Hisada, Azusa, Okafuji, Kazuhiro, Toya, Daisyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644427/ https://www.ncbi.nlm.nih.gov/pubmed/29067237 http://dx.doi.org/10.1016/j.jcte.2016.06.001

Ejemplares similares

Obesity may attenuate the HbA1c‐lowering effect of sitagliptin in Japanese type 2 diabetic patients
por: Bando, Yukihiro, et al.
Publicado: (2011)

Small Dense Low-Density Lipoprotein Cholesterol and the Risk of Coronary Heart Disease in a Japanese Community
por: Higashioka, Mayu, et al.
Publicado: (2020)

Estimation of the Presence of Small Dense Lipoprotein Cholesterol in Acute Ischemic Stroke
por: Manabe, Yasuhiro, et al.
Publicado: (2015)

Glycosuria medicated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report
por: Okada, Shuichi, et al.
Publicado: (2014)

Association among age, gender, menopausal status and small dense low-density lipoprotein cholesterol: a cross-sectional study
por: Izumida, Toshihide, et al.
Publicado: (2021)

Small, Dense Low-Density Lipoprotein-Cholesterol and Atherosclerosis: Relationship and Therapeutic Strategies
por: Jin, Xiao, et al.
Publicado: (2022)

Small Dense Low‐Density Lipoprotein Cholesterol Is the Most Atherogenic Lipoprotein Parameter in the Prospective Framingham Offspring Study
por: Ikezaki, Hiroaki, et al.
Publicado: (2021)

Small Dense Low-Density Lipoprotein Cholesterol and Carotid Intimal Medial Thickness Progression
por: Ikezaki, Hiroaki, et al.
Publicado: (2020)

Association of Small Dense Low-Density Lipoprotein Cholesterol with Stroke Risk, Severity and Prognosis
por: Zhou, Peiyang, et al.
Publicado: (2020)

Serum concentrations of small dense low‐density lipoprotein cholesterol and lipoprotein(a) are related to coronary arteriostenosis in Takayasu arteritis
por: Chen, Si, et al.
Publicado: (2021)

Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study
por: Iizuka, Takashi, et al.
Publicado: (2016)

Metabolic Properties of Lowdensity Lipoprotein (LDL) Triglycerides in Patients with Type 2 Diabetes, Comparison with Small Dense LDL-Cholesterol
por: Hirano, Tsutomu, et al.
Publicado: (2022)

Predictive value of small dense low-density lipoprotein cholesterol for cardiovascular events in Chinese elder diabetes mellitus patients
por: Xu, Li, et al.
Publicado: (2021)

Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
por: Hayashi, Toshiyuki, et al.
Publicado: (2017)

Small Dense Low-Density Lipoprotein Cholesterol and Cardiovascular Risk in Statin-Treated Patients with Coronary Artery Disease
por: Ishii, Junnichi, et al.
Publicado: (2022)

Small Dense Low-Density Lipoprotein Cholesterol Levels in Breakfast Skippers and Staple Foods Skippers
por: Arimoto, Masako, et al.
Publicado: (2023)

Association between measured or calculated small dense low‐density lipoprotein cholesterol and oxidized low‐density lipoprotein in subjects with or without type 2 diabetes mellitus
por: Kim, Hyun‐Ki, et al.
Publicado: (2022)

Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study
por: Iizuka, Takashi, et al.
Publicado: (2016)

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin
por: Kaku, Kohei, et al.
Publicado: (2021)

Correction to: Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
por: Hayashi, Toshiyuki, et al.
Publicado: (2017)

The influence of triglycerides on small dense low‐density lipoprotein cholesterol levels is attenuated in low low‐density lipoprotein‐cholesterol range: Implications for the negative results of the PROMINENT trial
por: Hirano, Tsutomu, et al.
Publicado: (2023)

Fatty liver in men is associated with high serum levels of small, dense low-density lipoprotein cholesterol
por: Hosoyamada, Kaori, et al.
Publicado: (2012)

Correlation between small and dense low‐density lipoprotein cholesterol and cardiovascular events in Beijing community population
por: Wang, Xiaona, et al.
Publicado: (2021)

Impact of Pemafibrate Therapy on Reducing Small Dense Low-Density-Lipoprotein-Cholesterol Levels in Patients with Hypertriglyceridemia
por: Hida, Yuki, et al.
Publicado: (2023)

The sodium–glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes
por: Okura, Tsuyoshi, et al.
Publicado: (2022)

Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo‐controlled trial
por: Kaku, Kohei, et al.
Publicado: (2019)

Low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio is the best surrogate marker for insulin resistance in non-obese Japanese adults
por: Kawamoto, Ryuichi, et al.
Publicado: (2010)

Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus
por: Kawata, Takehiro, et al.
Publicado: (2017)

Small dense low-density lipoprotein cholesterol was associated with future cardiovascular events in chronic kidney disease patients
por: Shen, Hao, et al.
Publicado: (2016)

Small-Dense Low-Density Lipoprotein Cholesterol: A Subclinical Marker for the Primary Prevention of Coronary Heart Disease
por: Kokubo, Yoshihiro, et al.
Publicado: (2020)

The Association of Small Dense Low-Density Lipoprotein Cholesterol and Coronary Heart Disease in Subjects at High Cardiovascular Risk
por: Higashioka, Mayu, et al.
Publicado: (2021)

Utilization of Small Dense Low-Density Lipoprotein Cholesterol Testing in Korean Patients Visiting Local Clinics and Hospitals
por: Choi, Rihwa, et al.
Publicado: (2022)

Low-Density Lipoprotein Cholesterol, Structural Atherosclerosis, and Functional Atherosclerosis in Older Japanese
por: Shimizu, Yuji, et al.
Publicado: (2022)

What is the Cause of Continuous and Marked Increase of Japanese High Density Lipoprotein Cholesterol?
por: Ueshima, Hirotsugu
Publicado: (2023)

Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes
por: Takahashi, Kiyohiko, et al.
Publicado: (2018)

Small dense low density lipoprotein-cholesterol and cholesterol ratios to predict arterial stiffness progression in normotensive subjects over a 5-year period
por: Li, Gang, et al.
Publicado: (2018)

Effect of Ezetimibe Monotherapy on Low-Density Lipoprotein Cholesterol and on Markers of Cholesterol Synthesis and Absorption in Japanese Patients With Hypercholesterolemia
por: Ohta, Akio, et al.
Publicado: (2017)

Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD
por: Takahashi, Hirokazu, et al.
Publicado: (2021)

Ipragliflozin/tozinameran: Diabetic ketoacidosis: 2 case reports
Publicado: (2022)

Correlation between of small dense low‐density lipoprotein cholesterol with acute cerebral infarction and carotid atherosclerotic plaque stability
por: QiaoZhen, Xue, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mf8bhjmom7470sgn6phishik65